Efimosfermin alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Efimosfermin alfa Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 3
Highest phase
10
Registered trials
6
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Phase 3 progression and GSK's acquisition support advancement, subject to long-duration liver outcomes and tolerability remaining favorable.
The central underwriting question is whether Efimosfermin alfa can convert its Fusion protein profile and FGF21R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Efimosfermin alfa (query alias: efimosfermin alfa) |
|---|---|
| Modality / target | Fusion protein; FGF21R; FGF21R modulators |
| Highest global status | Phase 3 |
| Originator | Novartis Pharmaceuticals Corp. |
| Active developers | GlaxoSmithKline (China) Investment Co. Ltd., GSK Plc |
The MCP disease footprint includes Fibrosis, Metabolic Dysfunction Associated Steatohepatitis, Compensated cirrhosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07701993 | Phase 3 | Not yet recruiting | 1740 | Time from randomization to an adjudicated composite liver-related clinical outcome |
| NCT07221188 | Phase 3 | Recruiting | 1250 | Number of participants with treatment-emergent adverse events (TEAEs) and TEAEs by severity |
| JPRN-jRCT2041260084 | Phase 3 | 募集前 | 103 | Time from randomization to an adjudicated composite clinical outcome: liver-related outcome comprises all-cause mortality; liver transplantation; occurrence of significant hepatic events. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
Phase 2; n=84; evaluation: Positive. Reported fields: AE(gastrointestinal events) = Most frequent adverse events were gastrointestinal events, which were transient and occurred within the first few weeks of treatment. ; AE(gastrointestinal events) = Most frequent adverse events were gastrointestinal events, which were transient and occurred within the first few weeks of treatment.
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
Phase 2; n=65; evaluation: Positive. Reported fields: TEAE = 18 Pts ; TEAE = 11 Pts ; TEAE = 12 Pts
Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, The Liver Meeting
Phase 2; n=84; evaluation: Positive. Reported fields: Improvement in fibrosis by at least 2 stage with no worsening of NASH = 20.6 % ; Improvement in fibrosis by at least 2 stage with no worsening of NASH = 45.2 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Efimosfermin alfa addresses Fibrosis, Metabolic Dysfunction Associated Steatohepatitis, Compensated cirrhosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-05-14 | GSK acquires efimosfermin alfa from Boston Pharma for $2bn | Phase 2 | US$1,200.0M upfront; US$800.0M milestones |
| 2018-10-03 | Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Long pivotal timelines and clinical-outcome endpoint risk
- Concordance among histology, non-invasive biomarkers, and hard liver outcomes
- Chronic-use tolerability and adherence
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Phase 3 progression and GSK's acquisition support advancement, subject to long-duration liver outcomes and tolerability remaining favorable.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
